{
  "dashlets": [
    {
      "id": "1",
      "title": "Proportion of HIV+ cases given antiretrovial therapy during TB treatment (IMHIGO)",
      "link": "https://dhis2.jsi.com/dss/api/analytics.json?dimension=dx\\:lBwHq99UNwD;Cyai2ELIIB7;kkAUgKEL5Y7&dimension=pe\\:LAST_YEAR&filter=ou\\:LEVEL-1",
      "chartType": "map"
    },
    {
      "id": "2",
      "title": "MDR-TB treatment: proportion of bacteriologically confirmed Rifampicin Resistant (RR)-MDR-TB cases who have a negative culture at the end of six month of second line treatment",
      "link": "https://dhis2.jsi.com/dss/api/analytics.json?dimension=dx\\:rlL15PvDkYy;AuGkfbrEpZQ;fDa1Y18ms5Y;SYRGn8IWKRR;CWSvQRgvCe3&dimension=pe\\:LAST_YEAR&filter=ou\\:LEVEL-1",
      "chartType": "map"
    },
    {
      "id": "3",
      "title": "    Proportion of HIV+ cases given antiretrovial therapy during TB treatment [IMHIGO]",
      "link": "https://dhis2.jsi.com/dss/api/analytics.json?dimension=dx\\:svj927QZPsK&dimension=pe\\:LAST_12_MONTHS&filter=ou\\:LEVEL-1",
      "chartType": "line"
    },
    {
      "id": "4",
      "title": "MDR-TB treatment: proportion of bacteriologically confirmed Rifampicin Resistant (RR)-MDR-TB cases who have a negative culture at the end of six month of second line treatment",
      "link": "https://dhis2.jsi.com/dss/api/analytics.json?dimension=dx\\:CkZemJwCjaY;lzTZpvSOhpa;B5we1J65yM0;IICFRxhEnPP;S8R92L050Ic;h3Xq3ahEYXY;QrKPP3xvosw;VB9QcuqSwnW;zAFNP5XTkuI&dimension=pe\\:LAST_12_MONTHS&filter=ou\\:LEVEL-3",
      "chartType": "Line"
    }
  ]
}

